Draft Scoping Document
CTAF

Multiple Sclerosis: Draft Scoping Document Addendum

The Institute for Clinical and Economic Review (ICER) has released an addendum to the Draft Scoping Document on disease-modifying therapies (DMTs) for multiple sclerosis. The addendum will be subject to a special public comment period of four weeks to provide stakeholders the opportunity to comment on the modifications. The addendum was open to public comment until Friday, August 12.

View All Materials on this Topic or Go Back to View More Materials